These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31516600)

  • 1. Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer.
    Hong W; Wu Q; Zhang J; Zhou Y
    Oncol Lett; 2019 Oct; 18(4):3887-3895. PubMed ID: 31516600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
    Xu J; Jin B; Chu T; Dong X; Yang H; Zhang Y; Wu D; Lou Y; Zhang X; Wang H; Han B
    Lung Cancer; 2016 Jun; 96():87-92. PubMed ID: 27133756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of clinical outcomes of patients with non-small cell lung cancer harboring different types of epidermal growth factor receptor sensitive mutations after first-line EGFR-TKI treatment].
    Liu JJ; Zhang S; Wu CJ; Ma LX; Liu Y; Li H; Cui HX; Cheng Y
    Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):211-7. PubMed ID: 26988828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.
    Zheng Z; Jin X; Lin B; Su H; Chen H; Fei S; Zhao L; Deng X; Xie D; Xie C
    J Cancer; 2017; 8(4):597-605. PubMed ID: 28367239
    [No Abstract]   [Full Text] [Related]  

  • 7. The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer.
    Zhang Y; Chen G; Chen X; Fang W; Gao F; Yang Y; Zhao Y; Ma Y; Hong S; Zhang Z; Miao S; Wu M; Huang X; Luo Y; Zhou C; Gong R; Huang Y; Chen L; Zhou N; Zhao H; Zhang L
    J Cancer; 2017; 8(10):1865-1871. PubMed ID: 28819384
    [No Abstract]   [Full Text] [Related]  

  • 8. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
    Kaneda T; Hata A; Tomioka H; Tanaka K; Kaji R; Fujita S; Tomii K; Katakami N
    Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
    Kaneda T; Yoshioka H; Tamiya M; Tamiya A; Hata A; Okada A; Niwa T; Shiroyama T; Kanazu M; Ishida T; Katakami N
    BMC Cancer; 2018 Jan; 18(1):6. PubMed ID: 29291705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer.
    Jiang H; Zhu M; Li Y; Li Q
    Mol Clin Oncol; 2019 Sep; 11(3):301-308. PubMed ID: 31384460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.
    Imai H; Minemura H; Sugiyama T; Yamada Y; Kaira K; Kanazawa K; Kasai T; Kaburagi T; Minato K;
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):119-127. PubMed ID: 29737372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon
    Jung HA; Park S; Sun JM; Lee SH; Ahn JS; Ahn MJ; Park K
    Biology (Basel); 2020 Oct; 9(10):. PubMed ID: 33036377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study.
    Lin Y; Chen L; Li R; Liu X; Li Q; Cai J; Du Y; Zhao G; Wang X; Shen Z; Liao Y; Chen Y; Xie L; Zhou Y; Huang Y
    Front Oncol; 2023; 13():1156647. PubMed ID: 37881485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic implications of combining EGFR-TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19-Del or 21-L858R mutations: A real-world study.
    Liang S; Wang H; Zhang Y; Tian H; Li C; Hua D
    Cancer Med; 2024 Apr; 13(8):e7208. PubMed ID: 38659399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study.
    Yang W; Gao Y; Li X; Zhang J; Liu T; Feng X; Pan H; Yang X; Xie S; Feng X; Lv Z; Wang Y; Chen Z; He J
    World J Surg Oncol; 2017 Nov; 15(1):197. PubMed ID: 29110716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
    Lee VH; Tin VP; Choy TS; Lam KO; Choi CW; Chung LP; Tsang JW; Ho PP; Leung DK; Ma ES; Liu J; Shek TW; Kwong DL; Leung TW; Wong MP
    J Thorac Oncol; 2013 Sep; 8(9):1148-55. PubMed ID: 23945384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
    Zheng Z; Xie D; Su H; Lin B; Zhao L; Deng X; Chen H; Fei S; Jin X; Xie C
    Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of neoadjuvant
    Xiong Y; Bian D; Huang Z; Yu H; Huang J; Zhang P; He W; Liu H
    Front Oncol; 2023; 13():1034897. PubMed ID: 36776292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.